Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
unable to find appropriate candidates
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There is an urgent need to develop hand transplant programs in this country. To this end, the University of Michigan Hospital and Health Systems is developing such an interdisciplinary program. The Transplant Center would like to track the patient experience from pre-operative care through surgery and post-operative care.
Detailed information will be collected from the patient medical records, including: Pre-operative screening, demographics, medications; Surgical information ; Post-operative inpatient and out-patient care; laboratory and other test results; physical assessments, psychological assessments and quality of life assessments.
Vascularized composite tissue allotransplantation (VCA) is the transplantation of multiple tissues containing skin, muscle, bone, joint, cartilage, nerve, tendon, vessels. VCA is useful for functional restoration of patients with severe tissue loss as encountered with massive burns, traumatic injuries, congenital anomalies, and following tumor resection. VCA, and specifically hand transplantation, combines the technical excellence of hand surgery/microsurgery with the complex multidisciplinary care rendered in modern solid organ transplantation. The technical demands of hand transplantation, enhanced donor antigen burden of the hand allograft, and complex psychosocial issues pertaining to the recipient account for much of the discrepancy between these 2 related fields.
Detailed information will be collected from the patient medical records, including: Pre-operative screening, demographics, medications; surgical information ; post-operative inpatient and out-patient care; laboratory and other test results; physical assessments, psychological assessments and quality of life assessments.
Specific outcomes will include allograft survival, allograft rejection, allograft functionality, and quality of life from transplant through 5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Allograft survival | Graft survival will be evaluated at transplant, days 14, then monthly in year 1, then yearly years 2-5 | Transplant through end of study (5 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Immunosuppression requirements | immunosuppression will be documented throughout study | Transplant through end of study (5 years) |
| Allograft rejection | Skin and muscle biopsies will be performed days 14, then monthly in year 1, then yearly years 2-5. Donor specific antibody will also be measured at these timepoints |
| Measure | Description | Time Frame |
|---|---|---|
| Cost and utilization information | cost and utilization of service will be tracked | Transplant through end of study (5 years) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients who have had traumatic hand transplantation below the elbow.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | United States |
Not provided
Not provided
Not provided
Not provided
| Transplant through end of study (5 years) |
| Allograft Function | Outcomes questionnaires will be completed by patient at post-transplant 3, 6, 12 months, and every year thereafter up to 5 years | Transplant through end of study (5 years) |
| Quality of life | SF-36 survey results will be collected before transplant and at various time points post transplant | Transplant through end of study (5 years) |